Blueprint Medicines Corp (NASDAQ: BPMC) closed the day trading at $87.97 up 1.32% from the previous closing price of $86.82. In other words, the price has increased by $+1.15 from its previous closing price. On the day, 1574890 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of BPMC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 5.93 whereas as Long-Term Debt/Eq ratio is at 5.30.
On August 21, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $65 to $66.
Wells Fargo Upgraded its Equal Weight to Overweight on July 31, 2023, whereas the target price for the stock was revised from $55 to $82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Landsittel Michael sold 13,734 shares for $87.78 per share. The transaction valued at 1,205,606 led to the insider holds 47,286 shares of the business.
Hurley Ariel sold 4,549 shares of BPMC for $399,213 on Mar 15 ’24. The PRINCIPAL ACCOUNTING OFFICER now owns 14,913 shares after completing the transaction at $87.76 per share. On Mar 13 ’24, another insider, Lee Philina, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 8,023 shares for $90.40 each. As a result, the insider received 725,277 and left with 34,729 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5.31B and an Enterprise Value of 4.93B. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.60 while its Price-to-Book (P/B) ratio in mrq is 41.18. Its current Enterprise Value per Revenue stands at 19.78 whereas that against EBITDA is -10.49.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $101.00, while it has fallen to a 52-week low of $41.54. The 50-Day Moving Average of the stock is 85.02, while the 200-Day Moving Average is calculated to be 66.34.
Shares Statistics:
Over the past 3-months, BPMC traded about 812.30K shares per day on average, while over the past 10 days, BPMC traded about 890.62k shares per day. A total of 61.15M shares are outstanding, with a floating share count of 59.79M. Insiders hold about 2.36% of the company’s shares, while institutions hold 105.00% stake in the company. Shares short for BPMC as of Feb 29, 2024 were 5.14M with a Short Ratio of 6.32, compared to 4.6M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.39% and a Short% of Float of 11.28%.
Earnings Estimates
Current recommendations for the stock of the company come from 15 analysts. On average, analysts expect EPS of -$1.66 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.8, while EPS last year was -$2.15. The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.22 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.37 and -$6.28 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$2.78, with 15 analysts recommending between -$0.27 and -$6.46.
Revenue Estimates
14 analysts predict $80.34M in revenue for the current quarter. It ranges from a high estimate of $86.7M to a low estimate of $72M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $63.29M, an estimated increase of 26.90% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $91.95M, an increase of 102.20% over than the figure of $26.90% in the same quarter last year. There is a high estimate of $101.9M for the next quarter, whereas the lowest estimate is $87M.
A total of 16 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $449M, while the lowest revenue estimate was $372M, resulting in an average revenue estimate of $392.72M. In the same quarter a year ago, actual revenue was $249.38M, up 57.50% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $596.03M in the next fiscal year. The high estimate is $738.9M and the low estimate is $481.18M. The average revenue growth estimate for next year is up 51.80% from the average revenue estimate for this year.
